Search Press releases

7 Mar 2025

BIMZELX[®] (bimekizumab-bkzx) five-year data at AAD 2025 showed sustained skin clearance and long-term efficacy in moderate-to-severe plaque psoriasis

Read More
7 Mar 2025

BIMZELX[®] (bimekizumab-bkzx) two-year data at AAD showed potential to eliminate draining tunnels in hidradenitis suppurativa (HS), and reduction in disease burden

Read More
27 Feb 2025

On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

Read More
12 Feb 2025

BIMZELX[®]▼(bimekizumab) two-year data at EHSF 2025 demonstrate sustained disease control in hidradenitis suppurativa (HS)

Read More
31 Jan 2025

RYSTIGGO[®]▼(rozanolixizumab), for generalized myasthenia gravis (gMG), receives EU approval for two new administration methods

Read More
15 Jan 2025

UCB showcases decade of growth and Patient Value Strategy driving differentiated innovation

Read More

Stay up-to-date on the latest news and information from UCB